Aurinia Pharmaceuticals Inc. (AUPH): R&D Expense
$32.51M
Year ended 2025-12-31
$39.85M
Trailing 12 months to 2026-06-30
-10.3%
3-year compound annual growth
-8.4%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $32.51M | +56.4% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $20.79M | -58.1% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $49.64M | +10.3% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $44.99M | -12.0% | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | $51.14M | +1.6% | 2024-02-15, From 2021-01-01 |
| 2020-12-31 | $50.33M | -4.8% | 2023-02-28, From 2020-01-01 |
| 2019-12-31 | $52.87M | +27.8% | 2022-02-28, From 2019-01-01 |
| 2018-12-31 | $41.38M | n/a | 2021-02-24, From 2018-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | 2025-12-31 | $32.51M | +56.4% |
| Summit Therapeutics Inc. (SMMT) | 2025-12-31 | $537.67M | +256.6% |
| Kiniksa Pharmaceuticals International, plc (KNSA) | 2025-12-31 | $96.85M | -13.2% |
| Cryoport, Inc. (CYRX) | 2025-12-31 | $17.04M | -3.8% |
| Kura Oncology, Inc. (KURA) | 2025-12-31 | $251.07M | +47.7% |
| Vera Therapeutics, Inc. (VERA) | 2025-12-31 | $215.26M | +70.6% |
| NewAmsterdam Pharma Co N.V. (NAMS) | 2025-12-31 | $141.83M | -6.3% |
| Maravai Lifesciences Holdings, Inc. (MRVI) | 2025-12-31 | $17.40M | -9.5% |
| Spyre Therapeutics, Inc. (SYRE) | 2025-12-31 | $171.65M | +5.4% |
Compare AUPH, SMMT, KNSA, CYRX side by side · Screen every company in Pharmaceutical Preparations ↗